Merck's Financial Update: Cost Cuts, Narrowed Outlook, and Key Drug Performance

Financial Performance and Outlook

• 📉 Merck reported a 2% slip in revenue compared to the prior year, marking its first revenue miss since April 2021.
• 🎯 The company is narrowing its full-year revenue and earnings guidance, indicating a more conservative outlook.
• 💰 Plans are in place to implement $3 billion in cost cuts by the end of 2027.

Key Drug Performance and Challenges

• 💡 Keytruda, described as one of the greatest drugs in history, continues to show promise in fighting different cancers, with new applications being discovered.
• ⚠️ However, the company faces the challenge of exclusivity not lasting forever for its blockbuster drugs like Keytruda.
• 📊 While Keytruda's sales were down 55% in the quarter, it's noted that the company is not as heavily invested in the weight loss arena as competitors like Eli Lilly.

Stock Performance and Shareholder Value

• 📈 Merck's stock performance is described as sad underperformance relative to the S&P and its peers.
• 💰 Shareholders have received a dividend, but the overall stock performance has been disappointing, especially considering the yield at previous price points.